Is SGLT2 Inhibitors a Better Prophylactic Agent Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease? A Multicenter Prospective Randomized Controlled Study
试验速览
- 阶段
- 不适用
- 入组人数
- 800
- 主要终点
- SGLT2i proves protective effect
研究概览
简要总结
We will look for the possible effect of SGLT2i as a single agent to prevent post-contrast Acute Kidney Injury in diabetic kidney disease.
详细描述
Population of Study o Group 1 :
- st group will receive normal saline 10ml/kg over 6 hours before and 6 hours after radiocontrast.
o Group 2 : 2. nd group will receive allopurinol 300 mg and linagliptin 5 mg once daily
o Group 3 : 3. rd group will receive the SGLT2i empagliflosin 25 mg once daily
o Group 4 : 4. thwill receive allopurinol and empagliflosin.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: more than30years, Diabetes, Diabetic kidney disease, GFR: more than30ml/min/1.73m2
排除标准
- •Diabetics Patients with GFR less than 30 mL/min/1.73 m2.
研究组 & 干预措施
Group 3
3rd group will receive the SGLT2i empagliflosin 25 mg once daily
干预措施: Empagliflozin 25 MG (Drug)
Group 4
4thwill receive allopurinol and empagliflosin.
干预措施: Empagliflozin 25 MG (Drug)
结局指标
主要结局
SGLT2i proves protective effect
时间窗: 72hours after contrast
SGLT2i shows protected the kidneys against contrast injury
次要结局
- SGLT2i is non inferior to allopurinol(72hours after contrast)
研究者
Ahmed Abdelkawi Hammad
Lecturer of internal medicine
Fayoum University